<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8796384</article-id>
    <article-id pub-id-type="pmid">34849593</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btab726</article-id>
    <article-id pub-id-type="publisher-id">btab726</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Original Papers</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Data and Text Mining</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Plasma protein binding prediction focusing on residue-level features and circularity of cyclic peptides by deep learning</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9004-5485</contrib-id>
        <name>
          <surname>Li</surname>
          <given-names>Jianan</given-names>
        </name>
        <aff><institution>Department of Computer Science, School of Computing, Tokyo Institute of Technology</institution>, Meguro-ku, Tokyo 152-8550, <country country="JP">Japan</country></aff>
        <aff><institution>AIST-TokyoTech Real World Big-Data Computation Open Innovation Laboratory (RWBC-OIL), National Institute of Advanced Industrial Science and Technology</institution>, Tsukuba, Ibaraki 305-8560, <country country="JP">Japan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0224-0035</contrib-id>
        <name>
          <surname>Yanagisawa</surname>
          <given-names>Keisuke</given-names>
        </name>
        <aff><institution>Department of Computer Science, School of Computing, Tokyo Institute of Technology</institution>, Meguro-ku, Tokyo 152-8550, <country country="JP">Japan</country></aff>
        <aff><institution>Middle-Molecule IT-based Drug Discovery Laboratory (MIDL), Tokyo Institute of Technology</institution>, Kawasaki, Kanagawa 210-0821, <country country="JP">Japan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yoshikawa</surname>
          <given-names>Yasushi</given-names>
        </name>
        <aff><institution>Department of Computer Science, School of Computing, Tokyo Institute of Technology</institution>, Meguro-ku, Tokyo 152-8550, <country country="JP">Japan</country></aff>
        <aff><institution>Middle-Molecule IT-based Drug Discovery Laboratory (MIDL), Tokyo Institute of Technology</institution>, Kawasaki, Kanagawa 210-0821, <country country="JP">Japan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0120-1643</contrib-id>
        <name>
          <surname>Ohue</surname>
          <given-names>Masahito</given-names>
        </name>
        <aff><institution>Department of Computer Science, School of Computing, Tokyo Institute of Technology</institution>, Meguro-ku, Tokyo 152-8550, <country country="JP">Japan</country></aff>
        <aff><institution>Middle-Molecule IT-based Drug Discovery Laboratory (MIDL), Tokyo Institute of Technology</institution>, Kawasaki, Kanagawa 210-0821, <country country="JP">Japan</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2863-8703</contrib-id>
        <name>
          <surname>Akiyama</surname>
          <given-names>Yutaka</given-names>
        </name>
        <xref rid="btab726-cor1" ref-type="corresp"/>
        <aff><institution>Department of Computer Science, School of Computing, Tokyo Institute of Technology</institution>, Meguro-ku, Tokyo 152-8550, <country country="JP">Japan</country></aff>
        <aff><institution>Middle-Molecule IT-based Drug Discovery Laboratory (MIDL), Tokyo Institute of Technology</institution>, Kawasaki, Kanagawa 210-0821, <country country="JP">Japan</country></aff>
        <!--akiyama@c.titech.ac.jp-->
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Lu</surname>
          <given-names>Zhiyong</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btab726-cor1">To whom correspondence should be addressed. <email>akiyama@c.titech.ac.jp</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <day>15</day>
      <month>2</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2021-11-22">
      <day>22</day>
      <month>11</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>22</day>
      <month>11</month>
      <year>2021</year>
    </pub-date>
    <volume>38</volume>
    <issue>4</issue>
    <fpage>1110</fpage>
    <lpage>1117</lpage>
    <history>
      <date date-type="received">
        <day>14</day>
        <month>6</month>
        <year>2021</year>
      </date>
      <date date-type="rev-recd">
        <day>22</day>
        <month>9</month>
        <year>2021</year>
      </date>
      <date date-type="editorial-decision">
        <day>11</day>
        <month>10</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>11</day>
        <month>10</month>
        <year>2021</year>
      </date>
      <date date-type="corrected-typeset">
        <day>26</day>
        <month>11</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2021. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2021</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btab726.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>In recent years, cyclic peptide drugs have been receiving increasing attention because they can target proteins that are difficult to be tackled by conventional small-molecule drugs or antibody drugs. Plasma protein binding rate (<inline-formula id="IE1"><mml:math id="IM1" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula>) is a significant pharmacokinetic property of a compound in drug discovery and design. However, due to structural differences, previous computational prediction methods developed for small-molecule compounds cannot be successfully applied to cyclic peptides, and methods for predicting the PPB rate of cyclic peptides with high accuracy are not yet available.</p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <p>Cyclic peptides are larger than small molecules, and their local structures have a considerable impact on PPB; thus, molecular descriptors expressing residue-level local features of cyclic peptides, instead of those expressing the entire molecule, as well as the circularity of the cyclic peptides should be considered. Therefore, we developed a prediction method named CycPeptPPB using deep learning that considers both factors. First, the macrocycle ring of cyclic peptides was decomposed residue by residue. The residue-based descriptors were arranged according to the sequence information of the cyclic peptide. Furthermore, the circular data augmentation method was used, and the circular convolution method CyclicConv was devised to express the cyclic structure. CycPeptPPB exhibited excellent performance, with mean absolute error (MAE) of 4.79% and correlation coefficient (<italic toggle="yes">R</italic>) of 0.92 for the public drug dataset, compared to the prediction performance of the existing PPB rate prediction software (<inline-formula id="IE2"><mml:math id="IM2" display="inline" overflow="scroll"><mml:mrow><mml:mtext>MAE</mml:mtext><mml:mo>=</mml:mo><mml:mn>15.08</mml:mn><mml:mo>%</mml:mo><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.63</mml:mn></mml:mrow></mml:math></inline-formula>).</p>
      </sec>
      <sec id="s3">
        <title>Availability and implementation</title>
        <p>The data underlying this article are available in the online supplementary material. The source code of CycPeptPPB is available at <ext-link xlink:href="https://github.com/akiyamalab/cycpeptppb" ext-link-type="uri">https://github.com/akiyamalab/cycpeptppb</ext-link>.</p>
      </sec>
      <sec id="s5">
        <title>Supplementary information</title>
        <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics</italic> online.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Program for Building Regional Innovation Ecosystems ‘Program to Industrialize an Innovative Middle Molecule Drug Discovery Flow through Fusion of Computational Drug Design and Chemical Synthesis Technology</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Ministry of Education, Culture, Sports, Science and Technology (MEXT); KAKENHI</institution>
          </institution-wrap>
        </funding-source>
        <award-id>17H01814</award-id>
        <award-id>20H04280</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Japan Society for the Promotion of Science (JSPS)</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)</institution>
          </institution-wrap>
        </funding-source>
        <award-id>JP20am0101112</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Japan Agency for Medical Research and Development (AMED)</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="8"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Conventional small-molecule drugs and antibody drugs cannot interact with 75–80% of potential drug targets (<xref rid="btab726-B31" ref-type="bibr">Verdine and Walensky, 2007</xref>). Under these circumstances, peptide drug discovery is gaining attention because peptide drugs, unlike conventional small-molecule drugs or antibody drugs, can interact with proteins recruited in important protein–protein interactions (PPIs) (<xref rid="btab726-B7" ref-type="bibr">Cary <italic toggle="yes">et al.</italic>, 2017</xref>). However, limitations of conventional linear peptides, such as lower stability against degrading enzymes, unsatisfactory selectivity and cell membrane permeability, have not yet been resolved (<xref rid="btab726-B6" ref-type="bibr">Cardote and Ciulli, 2016</xref>; <xref rid="btab726-B32" ref-type="bibr">Vinogradov <italic toggle="yes">et al.</italic>, 2019</xref>). In contrast to linear peptides, cyclic peptides have a macrocyclic structure. Macrocyclization imparts a degree of conformational restraint and functional group modification of the cyclized part and contributes to stronger stability and more selective interaction with the target protein (<xref rid="btab726-B32" ref-type="bibr">Vinogradov <italic toggle="yes">et al.</italic>, 2019</xref>). Therefore, cyclic peptide drugs are thought to improve many pharmacological properties of linear peptides and have favorable properties, such as high target specificity and good potency (<xref rid="btab726-B5" ref-type="bibr">Bhat <italic toggle="yes">et al.</italic>, 2015</xref>; <xref rid="btab726-B7" ref-type="bibr">Cary <italic toggle="yes">et al.</italic>, 2017</xref>). Owing to these advantages, more than 40 cyclic peptide drugs were clinically tested, in 2017, and one cyclic peptide drug has been launched to the market per year on average (<xref rid="btab726-B36" ref-type="bibr">Zorzi <italic toggle="yes">et al.</italic>, 2017</xref>).</p>
    <p>However, there remains a challenge related to the pharmacokinetic properties of cyclic peptide drugs (<xref rid="btab726-B7" ref-type="bibr">Cary <italic toggle="yes">et al.</italic>, 2017</xref>; <xref rid="btab726-B32" ref-type="bibr">Vinogradov <italic toggle="yes">et al.</italic>, 2019</xref>). Non-ideal pharmacokinetic properties have accounted for about 40% of failures in the traditional drug discovery process (<xref rid="btab726-B21" ref-type="bibr">Prentis <italic toggle="yes">et al.</italic>, 1988</xref>). Hence, for drug development, it is important to estimate the absorption, distribution, metabolism, excretion and toxicity (ADME-Tox) of compounds at an early stage. Plasma protein binding (PPB) is the reversible binding of compounds to plasma proteins, including serum albumin, hemoglobin and α-acid glycoproteins, and has a substantial effect on the compound ADME-Tox. PPB strongly affects drug distribution and pharmacokinetic behavior with consequences in overall pharmacological action (<xref rid="btab726-B19" ref-type="bibr">Lambrinidis <italic toggle="yes">et al.</italic>, 2015</xref>). Thus, the rate of binding to plasma proteins (<inline-formula id="IE3"><mml:math id="IM3" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula>) for a specific drug is a key indicator for lead optimization. Since experimental determination of <inline-formula id="IE4"><mml:math id="IM4" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula> is time consuming, fast computational PPB rate prediction methods are used in the early stage of the drug discovery process for traditional small molecules (<xref rid="btab726-B19" ref-type="bibr">Lambrinidis <italic toggle="yes">et al.</italic>, 2015</xref>).</p>
    <p>Previous PPB rate prediction methods for small molecules can be categorized into the following three approaches: ligand-based methods (<xref rid="btab726-B15" ref-type="bibr">Ingle <italic toggle="yes">et al.</italic>, 2016</xref>; <xref rid="btab726-B27" ref-type="bibr">Sun <italic toggle="yes">et al.</italic>, 2018</xref>; <xref rid="btab726-B33" ref-type="bibr">Watanabe <italic toggle="yes">et al.</italic>, 2018</xref>; <xref rid="btab726-B35" ref-type="bibr">Zhu <italic toggle="yes">et al.</italic>, 2013</xref>), structure-based methods (<xref rid="btab726-B13" ref-type="bibr">Gumede <italic toggle="yes">et al.</italic>, 2012</xref>; <xref rid="btab726-B17" ref-type="bibr">Katrina <italic toggle="yes">et al.</italic>, 2014</xref>) and composite methods that use both ligand and structure-based methods (<xref rid="btab726-B9" ref-type="bibr">Chen and Chen, 2012</xref>; <xref rid="btab726-B20" ref-type="bibr">Li <italic toggle="yes">et al.</italic>, 2011</xref>; <xref rid="btab726-B37" ref-type="bibr">Zsila <italic toggle="yes">et al.</italic>, 2011</xref>). The ligand-based approach uses various molecular descriptors calculated from the ligand molecule structure to establish quantitative structure–activity relationship (QSAR) models. The descriptors of the hydrophobicity index, such as the octanol–water partition coefficient (LogP), are generally the most important features for ligand-based methods (<xref rid="btab726-B19" ref-type="bibr">Lambrinidis <italic toggle="yes">et al.</italic>, 2015</xref>). For instance, <xref rid="btab726-B15" ref-type="bibr">Ingle <italic toggle="yes">et al.</italic> (2016)</xref> constructed several machine learning prediction models using 1045 small-molecule drugs and validated 200 independent compounds and 406 environmentally relevant ToxCast chemicals. The best model exhibits prediction accuracy with a mean absolute error (MAE) of 13.3% and coefficient of determination (<inline-formula id="IE5"><mml:math id="IM5" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula>) of 0.56.</p>
    <p>Nevertheless, since cyclic peptides have a relatively large structure, it is difficult to apply a prediction model for small-molecule drugs directly. Another issue is the limited number of available studies of cyclic peptides. Thus, finding descriptors that can be used for both cyclic peptides and small-molecule compounds has been a major research direction for the computational prediction of the PPB rate of cyclic peptides. <xref rid="btab726-B28" ref-type="bibr">Tajimi <italic toggle="yes">et al.</italic> (2018)</xref> constructed a prediction model using 1211 experimental data of small molecules, which were collected by <xref rid="btab726-B15" ref-type="bibr">Ingle <italic toggle="yes">et al.</italic> (2016)</xref>, and made PPB rate predictions for the 24 public DrugBank (<xref rid="btab726-B34" ref-type="bibr">Wishart <italic toggle="yes">et al.</italic>, 2018</xref>) cyclic peptides and 16 in-house cyclic peptides. Since the biophysical mechanism of PPB can be expected to be similar for both small molecules and cyclic peptides, their study focused on selecting descriptors with high generalizability from small-molecule training data. However, the method proposed by <xref rid="btab726-B28" ref-type="bibr">Tajimi <italic toggle="yes">et al.</italic> (2018)</xref> still has lower prediction accuracy (MAE of 21.6%, correlation coefficient (<italic toggle="yes">R</italic>) of 0.46) than that of the traditional prediction methods for small-molecule compounds and is not accurate enough for practical use. A feasible way to improve prediction accuracy is the consideration of a local structure, such as residue-level features of cyclic peptides. <xref rid="btab726-B25" ref-type="bibr">Schneider <italic toggle="yes">et al.</italic> (2017)</xref> investigated the structure–activity relationship of daptomycin and its derivatives and found a huge difference in PPB rates of daptomycin and acetyl-daptomycin. This difference is attributed to the tight hydrophobic contacts between the N-terminal fatty acyl chain of daptomycin and human serum albumin (HSA), the main component of the plasma proteins.</p>
    <p>Recently, deep learning methods have greatly contributed to several fields, such as speech recognition (<xref rid="btab726-B14" ref-type="bibr">Hinton <italic toggle="yes">et al.</italic>, 2012</xref>), object recognition (<xref rid="btab726-B10" ref-type="bibr">Eitel <italic toggle="yes">et al.</italic>, 2015</xref>) and protein tertiary structure prediction (<xref rid="btab726-B22" ref-type="bibr">Sato and Ishida, 2019</xref>). We thought the convolutional neural network (CNN) model would be suitable for the prediction of the PPB rate of cyclic peptides because it can express the number of residues, sequence information and partial features. In this study, we developed a prediction method called CycPeptPPB based on 1D-CNN that considers findings such as the influence of specific residues on the cyclic peptide PPB mechanism. Moreover, properties such as sequence information and cyclicity of the cyclic peptide were considered. To this end, first, the main chain was divided into residues to represent the partial structure. Using descriptors calculated from these residues, we proposed a 1D-CNN input format that can express the number of residues and sequence position information. In addition, we proposed two methods for expression of the circularity of the cyclic peptide, namely the circular convolution method CyclicConv and data augmentation method.</p>
  </sec>
  <sec>
    <title>2 Materials and methods</title>
    <sec>
      <title>2.1 Experimental data</title>
      <p>Studies investigating the PPB of cyclic peptides have not significantly advanced the field, and there are less than 30 peptides available. Our group spent a significant portion of our funding on synthesizing 16 cyclic peptides and conducting PPB rate measurement experiments (<xref rid="btab726-B28" ref-type="bibr">Tajimi <italic toggle="yes">et al.</italic>, 2018</xref>). However, the PPB rate of these peptides was very low, making it difficult to convert them into actual drug candidate compounds. Therefore, we collaborated with PeptiDream Inc., a leading company in cyclic peptide drug discovery, to provide us with many peptides with excellent PPB rates under a non-disclosure agreement. This allowed us to build a prediction model and to have a scientific discussion. In this study, private data concerning 347 peptides were provided by PeptiDream Inc., and 16 synthesized peptide data, and 17 approved peptide drug data with their experimentally determined PPB rates were used. <xref rid="btab726-F1" ref-type="fig">Figure  1</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref> show the distributions of the number of residues and the experimentally determined PPB rate of each cyclic peptide in each dataset. This section describes these three datasets and how they were split into training and test data.</p>
      <fig position="float" id="btab726-F1">
        <label>Fig. 1.</label>
        <caption>
          <p>Distributions of experimental data. (<bold>A</bold>) Number of residues. (<bold>B</bold>) Objective variable %<inline-formula id="IE6"><mml:math id="IM6" display="inline" overflow="scroll"><mml:mrow><mml:mi>P</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn><mml:mo>−</mml:mo><mml:mn>95</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>. Data of <inline-formula id="IE7"><mml:math id="IM7" display="inline" overflow="scroll"><mml:mrow><mml:mo>≤</mml:mo><mml:mn>50</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> is included in the leftmost bar, and data of <inline-formula id="IE8"><mml:math id="IM8" display="inline" overflow="scroll"><mml:mrow><mml:mo>≥</mml:mo><mml:mn>95</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> is included in the rightmost bar. Blue, orange and green bars indicate PD (PeptiDream), Tajimi and DrugBank datasets, respectively (distribution of the original %<italic toggle="yes">PPB</italic> is also shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1</xref>)</p>
        </caption>
        <graphic xlink:href="btab726f1" position="float"/>
      </fig>
      <sec>
        <label>2.1.1</label>
        <title>PeptiDream dataset</title>
        <p>The PeptiDream (PD) dataset contained 347 cyclic peptides designed and assayed by PeptiDream Inc. Details of their structural information were confidential; however, many peptides have N-methylated residues, reducing the number of hydrogen bond donors and increasing lipophilicity. A desirable property for drug candidates is <inline-formula id="IE9"><mml:math id="IM9" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi><mml:mo>≥</mml:mo><mml:mn>80</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula>, and higher lipophilicity tends to enhance PPB rate. Therefore, peptides with <inline-formula id="IE10"><mml:math id="IM10" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi><mml:mo>≥</mml:mo><mml:mn>80</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> occupied approximately 80% (272) of the whole dataset.</p>
      </sec>
      <sec>
        <title>2.1.2 Tajimi dataset</title>
        <p><xref rid="btab726-B28" ref-type="bibr">Tajimi <italic toggle="yes">et al.</italic> (2018)</xref> designed 16 cyclic peptides composed only of natural amino acids and conducted <inline-formula id="IE11"><mml:math id="IM11" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula> measurement experiments using the equilibrium dialysis method. In this study, these 16 cyclic peptides were used as the Tajimi dataset (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>). All these cyclic peptides were cyclized by disulfide bonds between the N-terminal and C-terminal cysteine residues. Unlike the PD dataset, the peptides in the Tajimi dataset have not been optimized for enhanced lipophilicity, such as N-methylation. Therefore, these compounds had extremely low <inline-formula id="IE12"><mml:math id="IM12" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula>; no compound had more than 90%, and only two compounds had more than 80%.</p>
      </sec>
      <sec>
        <label>2.1.3</label>
        <title>DrugBank dataset</title>
        <p><xref rid="btab726-B28" ref-type="bibr">Tajimi <italic toggle="yes">et al.</italic> (2018)</xref> collected 24 cyclic peptide PPB data from the FDA-approved drug public database DrugBank (<xref rid="btab726-B34" ref-type="bibr">Wishart <italic toggle="yes">et al.</italic>, 2018</xref>). From these data, we extracted 17 cases that were relatively similar in structure to the other two datasets (containing one ring and composed of five residues or more). These 17 public drug data were used as the DrugBank dataset in this study (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>). The range of <inline-formula id="IE13"><mml:math id="IM13" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula> was wide, eight compounds exceeded 80%. Unlike other datasets, some of these cyclic peptides contained fatty acid side chains; such peptides could exhibit high PPB rates even with low lipophilicity. Thus, the dataset was suitable for verifying the generalization performance of the prediction model and was used as external test data.</p>
      </sec>
      <sec>
        <label>2.1.4</label>
        <title>Splitting training and internal test data</title>
        <p>Since the peptides of the DrugBank dataset are structurally diverse and those of the PD and Tajimi datasets were relatively similar in structure, PD and Tajimi datasets were mixed and split into training and internal test data. The Kennard–Stone (KS) algorithm is a method for constructing a subset, which aims to uniformly cover a multidimensional space by maximizing the Euclidean distance between the vectors of the selected sample (<xref rid="btab726-B11" ref-type="bibr">Galvao <italic toggle="yes">et al.</italic>, 2005</xref>). We utilized the KS algorithm (Algorithm S1) to extract 10% data from the PD and Tajimi datasets (363 in total) as internal test data (37). The remaining data of PD and Tajimi datasets were used as training data (326).</p>
      </sec>
      <sec>
        <label>2.1.5</label>
        <title>Objective variable</title>
        <p>The objective variables used in PPB prediction studies for conventional small-molecule compounds can be broadly divided into two types: the type where the binding ratio is used as it is (<xref rid="btab726-B15" ref-type="bibr">Ingle <italic toggle="yes">et al.</italic>, 2016</xref>; <xref rid="btab726-B27" ref-type="bibr">Sun <italic toggle="yes">et al.</italic>, 2018</xref>; <xref rid="btab726-B33" ref-type="bibr">Watanabe <italic toggle="yes">et al.</italic>, 2018</xref>) and the type where it is used after logarithmic conversion (<xref rid="btab726-B20" ref-type="bibr">Li <italic toggle="yes">et al.</italic>, 2011</xref>; <xref rid="btab726-B35" ref-type="bibr">Zhu <italic toggle="yes">et al.</italic>, 2013</xref>). In the case of conventional small-molecule compounds, the PPB rate tends to be extremely high. Thus, logarithmic conversion, which has high resolution in the region of <inline-formula id="IE14"><mml:math id="IM14" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>90</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula>, is considered suitable for prediction. However, the PPB rate of cyclic peptides is generally lower than that of small-molecule compounds. The prediction method for cyclic peptides should practically focus on peptides with <inline-formula id="IE15"><mml:math id="IM15" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula> ranging from 50% to 95%, and logarithmic conversion is not so effective in the range. Cyclic peptides with <inline-formula id="IE16"><mml:math id="IM16" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula> less than 50% are very unlikely to be effective as drugs, and there is no need to precisely quantify <inline-formula id="IE17"><mml:math id="IM17" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula> less than 50%. Therefore, in this study, an experimentally measured value of <inline-formula id="IE18"><mml:math id="IM18" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula> less than 50% was rounded to 50%, and <inline-formula id="IE19"><mml:math id="IM19" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula> higher than 95% was rounded to 95% (%<inline-formula id="IE20"><mml:math id="IM20" display="inline" overflow="scroll"><mml:mrow><mml:mi>P</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn><mml:mo>−</mml:mo><mml:mn>95</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, <xref rid="btab726-F1" ref-type="fig">Fig.  1B</xref>). </p>
      </sec>
    </sec>
    <sec>
      <title>2.2 Descriptor design</title>
      <sec>
        <label>2.2.1</label>
        <title>Division of the main chain of a cyclic peptide into residues</title>
        <p>The specific local structure of a cyclic peptide has great influence on the PPB rate (<xref rid="btab726-B25" ref-type="bibr">Schneider <italic toggle="yes">et al.</italic>, 2017</xref>). Thus, we expressed local structural information by dividing the main chain of a cyclic peptide into units of residues (strictly speaking, it may not match the residue; thus, it is referred to as the substructure hereafter). The division was applied for peptide bonds and disulfide bonds. However, if the peptide bond was simply hydrolyzed, a new hydrogen bond donor may be generated, and the original physicochemical properties of the cyclic peptide may not be expressed. Hence, the selection of the capping functional group is important. When calculating 2D descriptors of the substructures, the cleaved amide group and carboxyl group were methylated (add <inline-formula id="IE21"><mml:math id="IM21" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mtext>CH</mml:mtext></mml:mrow></mml:mrow><mml:mn>3</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>) and converted to an aldehyde group (add H), respectively. On the other hand, when calculating 3D descriptors of them, the cleaved amide group and carboxyl group were capped with ACE (acetyl group) and NME (N-methyl group). This was called ACE-NME protein capping, which is often used for structural stability of the protein during molecular dynamics (MD) simulations (<xref rid="btab726-B16" ref-type="bibr">Isegawa <italic toggle="yes">et al.</italic>, 2013</xref>; <xref rid="btab726-B38" ref-type="bibr">Zuo <italic toggle="yes">et al.</italic>, 2014</xref>). When dividing the disulfide bond, hydrogen atoms were added to both sulfur atoms. In addition, to completely express the properties of the local structure, amide bonds existing anywhere other than the macrocycle was not subject to division.</p>
      </sec>
      <sec>
        <label>2.2.2</label>
        <title>Calculation of descriptors</title>
        <p>A total of 323 descriptors consisting of 206 2D descriptors and 117 3D descriptors were calculated by the MOE software (version 2019.01) (<xref rid="btab726-B8" ref-type="bibr">Chemical Computing Group Inc., 2019</xref>). The details of the 3D descriptors calculation are described in <xref rid="sup1" ref-type="supplementary-material">Supplementary Text S1</xref>. Descriptors calculated from both the whole peptide (whole-peptide descriptors) and each substructure (substructure descriptors) were standardized using Z-score as <inline-formula id="IE22"><mml:math id="IM22" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>z</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mo>μ</mml:mo></mml:mrow><mml:mo>σ</mml:mo></mml:mfrac></mml:mrow></mml:math></inline-formula> (<italic toggle="yes">μ</italic> is the average value of whole-peptide descriptor <bold><italic toggle="yes">x</italic></bold>, and <italic toggle="yes">σ</italic> is the standard deviation of <bold><italic toggle="yes">x</italic></bold>). In the case of substructure descriptors, each descriptor value for a specific substructure is weighted based on its appearance frequency within the experimental data used (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2</xref>). Whole-peptide predictors were used to select descriptors and construct comparison models, and substructure descriptors were used to construct baseline and CycPeptPPB models.</p>
      </sec>
    </sec>
    <sec>
      <title>2.3 Descriptor selection</title>
      <sec>
        <label>2.3.1</label>
        <title>Preprocessing of whole-peptide descriptors</title>
        <p>To remove the meaningless descriptors for PPB prediction, preprocessing based on whole-peptide descriptors was performed.
</p>
        <list list-type="order">
          <list-item>
            <p>Whole-peptide descriptors with values that were constant among all cyclic peptides were removed (<inline-formula id="IE23"><mml:math id="IM23" display="inline" overflow="scroll"><mml:mrow><mml:mn>323</mml:mn><mml:mo> </mml:mo><mml:mo>→</mml:mo><mml:mo> </mml:mo><mml:mn>294</mml:mn></mml:mrow></mml:math></inline-formula> descriptors).</p>
          </list-item>
          <list-item>
            <p>For whole-peptide descriptor pairs with an absolute value of the correlation coefficient of 0.95 or more, the one with a lower correlation with the objective variable %<inline-formula id="IE24"><mml:math id="IM24" display="inline" overflow="scroll"><mml:mrow><mml:mi>P</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn><mml:mo>−</mml:mo><mml:mn>95</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> was removed (<inline-formula id="IE25"><mml:math id="IM25" display="inline" overflow="scroll"><mml:mrow><mml:mn>294</mml:mn><mml:mo> </mml:mo><mml:mo>→</mml:mo><mml:mo> </mml:mo><mml:mn>147</mml:mn></mml:mrow></mml:math></inline-formula> descriptors).</p>
          </list-item>
        </list>
        <p>These 147 whole-peptide descriptors are listed in the <xref rid="sup1" ref-type="supplementary-material">Supplementary Data</xref>.</p>
      </sec>
      <sec>
        <label>2.3.2</label>
        <title>Selection of highly interpretable descriptors</title>
        <p>The number of descriptors was still large, and further selection of feasible descriptors was needed. Bolasso (<xref rid="btab726-B2" ref-type="bibr">Bach, 2008</xref>) is a feature selection method that incorporates the bootstrap method into Lasso (<xref rid="btab726-B29" ref-type="bibr">Tibshirani, 1996</xref>) and can extract highly important feature sets. Thus, whole-peptide descriptors were selected using a method like Bolasso. The feature selection algorithm is described in Algorithm S2. Three descriptors, logP(o/w), PEOE_VSA–1 and logS, were selected as a result. The changes in the selected descriptors due to the Lasso hyperparameters <italic toggle="yes">α</italic> are discussed in Section 4. The same three substructure descriptors were selected to construct baseline and CycPeptPPB models.</p>
      </sec>
    </sec>
    <sec>
      <title>2.4 Designing prediction techniques suitable for cyclic peptides</title>
      <sec>
        <label>2.4.1</label>
        <title>Construction of 1D-CNN input feature map by substructure descriptors</title>
        <p>First, the main chain of the cyclic peptide was cut at the cyclized position. Next, the substructure descriptors were arranged in the center of the input layer as shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S3</xref> based on the sequence information, to generate the input feature map of the 1D-CNN model. This input method can express the number of substructures and sequence position information of the substructures.</p>
      </sec>
      <sec>
        <label>2.4.2</label>
        <title>Proposed convolution method (CyclicConv)</title>
        <p>The conventional 1D-CNN cannot express circularity. To overcome this limitation, we proposed a new convolution method that supplemented adjacent substructures at both ends of an input peptide sequence (CyclicConv, <xref rid="btab726-F2" ref-type="fig">Fig.  2A</xref>).</p>
        <fig position="float" id="btab726-F2">
          <label>Fig. 2.</label>
          <caption>
            <p>(<bold>A</bold>) Comparison of the conventional convolution method (1D-CNN) and the proposed convolution method (CyclicConv). In the case of kernel size of 3, substructure C is supplemented to the left of A and substructure A is supplemented to the right of C. By this operation, the information of CAB and BCA can be correctly acquired as a result of the CyclicConv. (<bold>B</bold>) Augmentation (rotation and translation) based on the sequence information</p>
          </caption>
          <graphic xlink:href="btab726f2" position="float"/>
        </fig>
      </sec>
      <sec>
        <label>2.4.3</label>
        <title>Augmentation for input feature map</title>
        <p>In addition to CyclicConv, we proposed data augmentation as a method to express cyclical structure. As shown in <xref rid="btab726-F2" ref-type="fig">Figure  2B</xref>, data augmentation was performed based on the rotation and translation of the input peptide sequence. The peptide with the largest number of substructures in the experimental data was composed of 15 substructures, and augmentation yields <inline-formula id="IE26"><mml:math id="IM26" display="inline" overflow="scroll"><mml:mrow><mml:mi>n</mml:mi><mml:mo>×</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="italic">Max</mml:mi><mml:mo>_</mml:mo><mml:mi mathvariant="italic">length</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo>=</mml:mo><mml:mn>15</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> feature map replicas from the cyclic peptide with <italic toggle="yes">n</italic> substructures (363 peptides <inline-formula id="IE27"><mml:math id="IM27" display="inline" overflow="scroll"><mml:mrow><mml:mo>→</mml:mo><mml:mo> </mml:mo><mml:mn>18</mml:mn><mml:mo> </mml:mo><mml:mn>999</mml:mn></mml:mrow></mml:math></inline-formula> replicas). In addition, augmentation can express cyclic information of cyclic peptides to some extent. Moreover, predictions can be performed based on relative position information rather than absolute position information of a sequence, leading to improved generalization performance and robustness of the prediction model.</p>
      </sec>
    </sec>
    <sec>
      <title>2.5 Architecture of prediction models</title>
      <sec>
        <label>2.5.1</label>
        <title>Baseline model and three CycPeptPPB models</title>
        <p>Using the input format of the 1D-CNN model described earlier, we constructed four CNN prediction models (a baseline model and the CycPeptPPB models 1, 2 and 3) based on substructure descriptors. These models were built with the Chainer framework (version 7.1.0) (<xref rid="btab726-B30" ref-type="bibr">Tokui <italic toggle="yes">et al.</italic>, 2015</xref>). The model using the ordinary convolutional method was used as the baseline model, and the model using CyclicConv was used as CycPeptPPB model 1. Furthermore, to assess the effect of augmentation, we devised CycPeptPPB model 2, which combines augmentation and the ordinary convolution method and CycPeptPPB model 3 that combines augmentation and CyclicConv. <xref rid="btab726-F3" ref-type="fig">Figure  3</xref> shows the basic architecture of these CNN models and differences among them.</p>
        <fig position="float" id="btab726-F3">
          <label>Fig. 3.</label>
          <caption>
            <p>Architecture of the baseline model and CycPeptPPB models 1, 2 and 3. The structure of the pooling layer and the fully connected layer was the same for all four models. In addition, all convolutional layers and fully connected layers used batch normalization</p>
          </caption>
          <graphic xlink:href="btab726f3" position="float"/>
        </fig>
        <p>Several efficient hyperparameter search methods based on Bayesian optimization have been widely used (<xref rid="btab726-B4" ref-type="bibr">Ban <italic toggle="yes">et al.</italic>, 2017</xref>). In this study, we used Optuna (version 2.2.0) (<xref rid="btab726-B1" ref-type="bibr">Akiba <italic toggle="yes">et al.</italic>, 2019</xref>) to optimize hyperparameters, including the number of convolutional layers and CyclicConv layers for each CNN model. The search range of target hyperparameters and their search results are shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Tables S3 and S4</xref>.</p>
      </sec>
      <sec>
        <label>2.5.2</label>
        <title>Comparison with conventional methods</title>
        <p>We also compared CycPeptPPB models with three conventional methods to assess the importance of using the substructure descriptor. ADMET Predictor (version 10.0) (<xref rid="btab726-B26" ref-type="bibr">Simulations Plus Inc., 2020</xref>) is an integrated suite of cheminformatics that examines how the molecular structure of a compound is related to the ADME-Tox properties. To compare the CycPeptPPB model with the existing PPB rate prediction software, we used ADMET Predictor as the comparison model 1. Additionally, an SVM model (comparison model 2) and RF model (comparison model 3) based on three selected whole-peptide descriptors were constructed. The hyperparameters of these two models were determined by grid search. The search range and optimal hyperparameters are shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S5</xref>.</p>
      </sec>
    </sec>
    <sec>
      <title>2.6 Evaluation method</title>
      <p><xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S4</xref> shows the overall flow of the model prediction accuracy evaluation. When using the data augmentation technique to increase the amount of experimental data, not only training but also test data input was augmented, and the average predicted value of all replicas was used as the final predicted value. MAE (%) and <italic toggle="yes">R</italic> were used as evaluation indices in this study. If the predicted value was less than 50%, it was rounded to 50%, and if it exceeded 95%, it was rounded to 95%. The definitions of these indices are shown in <xref rid="E1" ref-type="disp-formula">Equations (1)</xref> and <xref rid="E2" ref-type="disp-formula">(2)</xref>. Here, <italic toggle="yes">y<sub>i</sub></italic> is the experimental value of the <italic toggle="yes">i</italic>th data, and <inline-formula id="IE28"><mml:math id="IM28" display="inline" overflow="scroll"><mml:mrow><mml:mover accent="true"><mml:mi>y</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> is the average value of the experimental value. <inline-formula id="IE29"><mml:math id="IM29" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mi>y</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> is the predicted value of the <italic toggle="yes">i</italic>th data, and <inline-formula id="IE30"><mml:math id="IM30" display="inline" overflow="scroll"><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mover accent="true"><mml:mi>y</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> is the average value of the predicted values.
<disp-formula id="E1"><label>(1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:mtext>MAE</mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:mrow><mml:mo>|</mml:mo><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mover accent="true"><mml:mi>y</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>|</mml:mo></mml:mrow></mml:mrow><mml:mi>n</mml:mi></mml:mfrac></mml:mrow></mml:math></disp-formula>
 <disp-formula id="E2"><label>(2)</label><mml:math id="M2" display="block" overflow="scroll"><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mover accent="true"><mml:mi>y</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mover accent="true"><mml:mi>y</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mrow><mml:mover accent="true"><mml:mi>y</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msqrt><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mover accent="true"><mml:mi>y</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mover accent="true"><mml:mi>y</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:msqrt><mml:msqrt><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mrow><mml:mover accent="true"><mml:mi>y</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p>
      <p>From the viewpoint of compound screening, whether the PPB rate exceeded 80% was an important consideration for drug development. In addition, drugs with a high binding rate may differ significantly from drugs with a low binding rate in terms of tissue penetration and half-life (<xref rid="btab726-B23" ref-type="bibr">Scheife, 1989</xref>). Therefore, to select a better compound, it is important to evaluate whether the PPB rate in the region exceeds 80%. In this study, in addition to the prediction accuracy of <inline-formula id="IE31"><mml:math id="IM31" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula> from 50% to 95% (%<inline-formula id="IE32"><mml:math id="IM32" display="inline" overflow="scroll"><mml:mrow><mml:mi>P</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn><mml:mo>−</mml:mo><mml:mn>95</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>), the prediction accuracy of 80–95% was evaluated (<inline-formula id="IE33"><mml:math id="IM33" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi>P</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mn>80</mml:mn><mml:mo>−</mml:mo><mml:mn>95</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>). In the latter case, cyclic peptides with experimental values of 80% or more were selected as calculation targets from test data. The evaluation indices were calculated from these predicted values. Similarly, if the predicted value exceeded 95%, it was rounded to 95%.</p>
    </sec>
    <sec>
      <title>2.7 Analysis of prediction results by Saliency Score</title>
      <p>Cyclic peptides composed of natural amino acids of <italic toggle="yes">x</italic> residues have <inline-formula id="IE34"><mml:math id="IM34" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mn>20</mml:mn></mml:mrow></mml:mrow><mml:mi>x</mml:mi></mml:msup></mml:mrow></mml:math></inline-formula> combinations, and it is computationally impossible to perform a trial-and-error-based search of the entire space for a better PPB rate. Therefore, from the perspective of efficient design and optimization for the development of cyclic peptide drugs, determining which substructure enhances <inline-formula id="IE35"><mml:math id="IM35" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula> and which has no effect on <inline-formula id="IE36"><mml:math id="IM36" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula> is necessary. We analyzed the importance of each substructure using the Saliency Score defined with the Saliency Map and calculated the contribution of the partial substructure to the PPB rate prediction.</p>
      <p>The Saliency Map was originally defined as a heatmap that estimates the parts of a visual image to which people pay attention when viewing it. Many methods have been reported to calculate the Salience Map of deep learning models (<xref rid="btab726-B12" ref-type="bibr">Garcia-Diaz <italic toggle="yes">et al.</italic>, 2012</xref>; <xref rid="btab726-B18" ref-type="bibr">Kümmerer <italic toggle="yes">et al.</italic>, 2014</xref>), and VanillaGrad (<xref rid="btab726-B3" ref-type="bibr">Baehrens <italic toggle="yes">et al.</italic>, 2010</xref>) is one of the simplest methods. We applied it to calculate Saliency Score <inline-formula id="IE37"><mml:math id="IM37" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">s</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> for peptides <italic toggle="yes">i</italic> based on the input (feature map) <inline-formula id="IE38"><mml:math id="IM38" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> and output (predicted value) <inline-formula id="IE39"><mml:math id="IM39" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mi>y</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> as <inline-formula id="IE40"><mml:math id="IM40" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo>|</mml:mo><mml:mo>∂</mml:mo><mml:msub><mml:mrow><mml:mover accent="true"><mml:mi>y</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mo>∂</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>|</mml:mo></mml:mrow></mml:math></inline-formula>.</p>
    </sec>
  </sec>
  <sec>
    <title>3 Results</title>
    <sec>
      <title>3.1 PPB rate prediction results</title>
      <p>The prediction accuracy for internal test data and external test (DrugBank) data by all seven models is shown in <xref rid="btab726-T1" ref-type="table">Tables  1</xref> and <xref rid="btab726-T2" ref-type="table">2</xref>, respectively. In addition, the experimental <inline-formula id="IE41"><mml:math id="IM41" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula> and predicted <inline-formula id="IE42"><mml:math id="IM42" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula> for comparison model 1 (ADMET Predictor), CycPeptPPB model 1 (CyclicConv) and CycPeptPPB model 2 (augmentation) are plotted in <xref rid="btab726-F4" ref-type="fig">Figure  4</xref>, whereas the results for the other four models are plotted in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S5</xref>. According to the prediction results shown in <xref rid="btab726-T1" ref-type="table">Table  1</xref> (internal test data), comparison model 1 (ADMET Predictor) exhibited the worst prediction accuracy for test data (<inline-formula id="IE43"><mml:math id="IM43" display="inline" overflow="scroll"><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.60</mml:mn></mml:mrow></mml:math></inline-formula> in 50–95%). This result showed that the conventional method cannot accurately predict <inline-formula id="IE44"><mml:math id="IM44" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula> of cyclic peptides. Comparison model 2 (SVM) and comparison model 3 (RF), using the whole-peptide descriptors calculated from the entire cyclic peptide (<inline-formula id="IE45"><mml:math id="IM45" display="inline" overflow="scroll"><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.79</mml:mn></mml:mrow></mml:math></inline-formula> through 0.81 in 50–95%), exhibited higher prediction accuracy than the comparison model 1. The results indicated that the proposed whole-peptide descriptor selection method worked correctly and that the three descriptors, logP(o/w), PEOE_VSA-1 and logS, were appropriate for prediction. The baseline model and CycPeptPPB model 1 (CyclicConv), using substructure descriptors, obtained higher prediction accuracy than any of the comparison models (<inline-formula id="IE46"><mml:math id="IM46" display="inline" overflow="scroll"><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.88</mml:mn></mml:mrow></mml:math></inline-formula> through 0.89 in 50–95%). Both models exhibited similar prediction accuracies, and CyclicConv did not notably improve prediction accuracy compared to the baseline model. CycPeptPPB model 2 (augmentation) and CycPeptPPB model 3 (CyclicConv and augmentation) further improved prediction accuracy compared to the baseline model and CycPeptPPB model 1 (<inline-formula id="IE47"><mml:math id="IM47" display="inline" overflow="scroll"><mml:mrow><mml:mtext>MAE</mml:mtext><mml:mo>=</mml:mo><mml:mn>3.99</mml:mn></mml:mrow></mml:math></inline-formula>% through 4.06%, <inline-formula id="IE48"><mml:math id="IM48" display="inline" overflow="scroll"><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.90</mml:mn></mml:mrow></mml:math></inline-formula> in 50–95%).</p>
      <fig position="float" id="btab726-F4">
        <label>Fig. 4.</label>
        <caption>
          <p>Prediction results of CycPeptPPB model 1 (<bold>A</bold>), model 2 (<bold>B</bold>) and comparison model 1 (<bold>C</bold>), for internal test data (red) and external test data (green). The horizontal axis is experimental <inline-formula id="IE49"><mml:math id="IM49" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula>, the vertical axis is predicted <inline-formula id="IE50"><mml:math id="IM50" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula> of each method, and the dark background color shows the range over 80%</p>
        </caption>
        <graphic xlink:href="btab726f4" position="float"/>
      </fig>
      <table-wrap position="float" id="btab726-T1">
        <label>Table 1.</label>
        <caption>
          <p>Prediction accuracy of internal test data</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col valign="top" align="left" span="1"/>
            <col valign="top" align="left" span="1"/>
            <col valign="top" align="right" span="1"/>
            <col valign="top" align="right" span="1"/>
            <col valign="top" align="right" span="1"/>
            <col valign="top" align="right" span="1"/>
            <col valign="top" align="right" span="1"/>
            <col valign="top" align="right" span="1"/>
            <col valign="top" align="right" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th rowspan="1" colspan="1"><inline-formula id="IE51"><mml:math id="IM51" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula>  <break/>range</th>
              <th align="left" rowspan="1" colspan="1">Evaluation <break/>index</th>
              <th rowspan="1" colspan="1">Baseline <break/>model</th>
              <th rowspan="1" colspan="1">CycPeptPPB model 1</th>
              <th rowspan="1" colspan="1">CycPeptPPB model 2</th>
              <th rowspan="1" colspan="1">CycPeptPPB model 3</th>
              <th rowspan="1" colspan="1">Comparison model 1</th>
              <th rowspan="1" colspan="1">Comparison model 2</th>
              <th rowspan="1" colspan="1">Comparison model 3</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">50–95%</td>
              <td rowspan="1" colspan="1">MAE (%)</td>
              <td rowspan="1" colspan="1">5.09</td>
              <td rowspan="1" colspan="1">5.50</td>
              <td rowspan="1" colspan="1">
                <inline-formula id="IE52">
                  <mml:math id="IM52" display="inline" overflow="scroll">
                    <mml:mrow>
                      <mml:mi mathvariant="bold">3</mml:mi>
                      <mml:mo>.</mml:mo>
                      <mml:mi mathvariant="bold">99</mml:mi>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td rowspan="1" colspan="1">4.06</td>
              <td rowspan="1" colspan="1">11.17</td>
              <td rowspan="1" colspan="1">6.83</td>
              <td rowspan="1" colspan="1">7.86</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">R</italic>
              </td>
              <td rowspan="1" colspan="1">0.89</td>
              <td rowspan="1" colspan="1">0.88</td>
              <td rowspan="1" colspan="1">
                <inline-formula id="IE53">
                  <mml:math id="IM53" display="inline" overflow="scroll">
                    <mml:mrow>
                      <mml:mi mathvariant="bold">0</mml:mi>
                      <mml:mo>.</mml:mo>
                      <mml:mi mathvariant="bold">90</mml:mi>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td rowspan="1" colspan="1">
                <inline-formula id="IE54">
                  <mml:math id="IM54" display="inline" overflow="scroll">
                    <mml:mrow>
                      <mml:mi mathvariant="bold">0</mml:mi>
                      <mml:mo>.</mml:mo>
                      <mml:mi mathvariant="bold">90</mml:mi>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td rowspan="1" colspan="1">0.60</td>
              <td rowspan="1" colspan="1">0.81</td>
              <td rowspan="1" colspan="1">0.79</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">80–95%</td>
              <td rowspan="1" colspan="1">MAE (%)</td>
              <td rowspan="1" colspan="1">4.64</td>
              <td rowspan="1" colspan="1">3.85</td>
              <td rowspan="1" colspan="1">2.65</td>
              <td rowspan="1" colspan="1">
                <inline-formula id="IE55">
                  <mml:math id="IM55" display="inline" overflow="scroll">
                    <mml:mrow>
                      <mml:mi mathvariant="bold">2</mml:mi>
                      <mml:mo>.</mml:mo>
                      <mml:mi mathvariant="bold">00</mml:mi>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td rowspan="1" colspan="1">6.10</td>
              <td rowspan="1" colspan="1">3.65</td>
              <td rowspan="1" colspan="1">6.13</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">R</italic>
              </td>
              <td rowspan="1" colspan="1">
                <inline-formula id="IE56">
                  <mml:math id="IM56" display="inline" overflow="scroll">
                    <mml:mrow>
                      <mml:mi mathvariant="bold">0</mml:mi>
                      <mml:mo>.</mml:mo>
                      <mml:mi mathvariant="bold">94</mml:mi>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td rowspan="1" colspan="1">0.85</td>
              <td rowspan="1" colspan="1">0.93</td>
              <td rowspan="1" colspan="1">0.83</td>
              <td rowspan="1" colspan="1">0.37</td>
              <td rowspan="1" colspan="1">0.59</td>
              <td rowspan="1" colspan="1">0.66</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="tblfn1">
            <p><italic toggle="yes">Note</italic>: The best result for each evaluation index is indicated in bold.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap position="float" id="btab726-T2">
        <label>Table 2.</label>
        <caption>
          <p>Prediction accuracy of external test data (DrugBank dataset)</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col valign="top" align="left" span="1"/>
            <col valign="top" align="left" span="1"/>
            <col valign="top" align="right" span="1"/>
            <col valign="top" align="right" span="1"/>
            <col valign="top" align="right" span="1"/>
            <col valign="top" align="right" span="1"/>
            <col valign="top" align="right" span="1"/>
            <col valign="top" align="right" span="1"/>
            <col valign="top" align="right" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th rowspan="1" colspan="1"><inline-formula id="IE57"><mml:math id="IM57" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula>  <break/>range</th>
              <th align="left" rowspan="1" colspan="1">Evaluation index</th>
              <th rowspan="1" colspan="1">Baseline <break/>model</th>
              <th rowspan="1" colspan="1">CycPeptPPB model 1</th>
              <th rowspan="1" colspan="1">CycPeptPPB model 2</th>
              <th rowspan="1" colspan="1">CycPeptPPB model 3</th>
              <th rowspan="1" colspan="1">Comparison model 1</th>
              <th rowspan="1" colspan="1">Comparison model 2</th>
              <th rowspan="1" colspan="1">Comparison model 3</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">50–95%</td>
              <td rowspan="1" colspan="1">MAE (%)</td>
              <td rowspan="1" colspan="1">6.55</td>
              <td rowspan="1" colspan="1">15.60</td>
              <td rowspan="1" colspan="1">
                <inline-formula id="IE58">
                  <mml:math id="IM58" display="inline" overflow="scroll">
                    <mml:mrow>
                      <mml:mi mathvariant="bold">4</mml:mi>
                      <mml:mo>.</mml:mo>
                      <mml:mi mathvariant="bold">79</mml:mi>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td rowspan="1" colspan="1">8.97</td>
              <td rowspan="1" colspan="1">15.08</td>
              <td rowspan="1" colspan="1">13.31</td>
              <td rowspan="1" colspan="1">12.55</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">R</italic>
              </td>
              <td rowspan="1" colspan="1">0.89</td>
              <td rowspan="1" colspan="1">0.66</td>
              <td rowspan="1" colspan="1">
                <inline-formula id="IE59">
                  <mml:math id="IM59" display="inline" overflow="scroll">
                    <mml:mrow>
                      <mml:mi mathvariant="bold">0</mml:mi>
                      <mml:mo>.</mml:mo>
                      <mml:mi mathvariant="bold">92</mml:mi>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td rowspan="1" colspan="1">0.87</td>
              <td rowspan="1" colspan="1">0.63</td>
              <td rowspan="1" colspan="1">0.42</td>
              <td rowspan="1" colspan="1">0.50</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">80–95%</td>
              <td rowspan="1" colspan="1">MAE (%)</td>
              <td rowspan="1" colspan="1">7.69</td>
              <td rowspan="1" colspan="1">
                <inline-formula id="IE60">
                  <mml:math id="IM60" display="inline" overflow="scroll">
                    <mml:mrow>
                      <mml:mi mathvariant="bold">4</mml:mi>
                      <mml:mo>.</mml:mo>
                      <mml:mi mathvariant="bold">22</mml:mi>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td rowspan="1" colspan="1">6.17</td>
              <td rowspan="1" colspan="1">7.61</td>
              <td rowspan="1" colspan="1">9.64</td>
              <td rowspan="1" colspan="1">22.92</td>
              <td rowspan="1" colspan="1">20.53</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">R</italic>
              </td>
              <td rowspan="1" colspan="1">0.17</td>
              <td rowspan="1" colspan="1">0.13</td>
              <td rowspan="1" colspan="1">
                <inline-formula id="IE61">
                  <mml:math id="IM61" display="inline" overflow="scroll">
                    <mml:mrow>
                      <mml:mi mathvariant="bold">0</mml:mi>
                      <mml:mo>.</mml:mo>
                      <mml:mi mathvariant="bold">43</mml:mi>
                    </mml:mrow>
                  </mml:math>
                </inline-formula>
              </td>
              <td rowspan="1" colspan="1">0.14</td>
              <td rowspan="1" colspan="1">–0.41</td>
              <td rowspan="1" colspan="1">–0.56</td>
              <td rowspan="1" colspan="1">–0.50</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="tblfn2">
            <p><italic toggle="yes">Note</italic>: The best result for each evaluation index is indicated in bold.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>For the external test data, in contrast to the internal test data, all comparison models exhibited comparable accuracy in the range of 50–95%, as shown in <xref rid="btab726-T2" ref-type="table">Table  2</xref>. However, since comparison model 1 (ADMET Predictor) tended to predict high PPB rates for most cyclic peptides (about 70% or more, <xref rid="btab726-F4" ref-type="fig">Fig.  4C</xref>), the prediction accuracy was higher than comparison model 2 and 3 (SVM and RF, respectively) in the range of 80–95%. As CycPeptPPB model 1 (CyclicConv) also tended to predict high PPB rates for external test data, the MAE was the best among the models in the range of 80–95% (<xref rid="btab726-F4" ref-type="fig">Fig.  4A</xref>), whereas there was no correlation in the range of 80–95%. Overall, due to the difficulty in predicting PPB rates of peptides with fatty large side chains in the external test data, the prediction accuracy in the range of 80–95% was inferior to that in 50–95% for all seven prediction models (more detailed discussion was summarized in <xref rid="sup1" ref-type="supplementary-material">Supplementary Text S2</xref>). CycPeptPPB model 2 (augmentation) exhibited the best performance for the external test data (<xref rid="btab726-F4" ref-type="fig">Fig.  4B</xref>, <inline-formula id="IE62"><mml:math id="IM62" display="inline" overflow="scroll"><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>0.92</mml:mn></mml:mrow></mml:math></inline-formula> in 50–95%). CycPeptPPB model 3 (CyclicConv and augmentation) was not better than CycPeptPPB model 2. Accordingly, the CycPeptPPB model 2 was used as the representative model of this study.</p>
    </sec>
    <sec>
      <title>3.2 Important substructures contributing to PPB rate prediction</title>
      <p>The top 10 substructures (represented by original #IDs defined in this study) with the highest contributions calculated from the Saliency Score were <inline-formula id="IE63"><mml:math id="IM63" display="inline" overflow="scroll"><mml:mrow><mml:mo>#</mml:mo><mml:mn>100</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:mn>10</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mo>#</mml:mo><mml:mn>24</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mo>#</mml:mo><mml:mn>54</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mo>#</mml:mo><mml:mn>103</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mo>#</mml:mo><mml:mn>114</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mo>#</mml:mo><mml:mn>125</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mo>#</mml:mo><mml:mn>121</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mo>#</mml:mo><mml:mn>90</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:mn>11</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mo>#</mml:mo><mml:mn>118</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> and <inline-formula id="IE64"><mml:math id="IM64" display="inline" overflow="scroll"><mml:mrow><mml:mo>#</mml:mo><mml:mn>41</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:mn>14</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> (numbers in the parentheses indicate the number of cyclic peptides with the corresponding substructure). Among these substructures, <inline-formula id="IE65"><mml:math id="IM65" display="inline" overflow="scroll"><mml:mrow><mml:mo>#</mml:mo><mml:mn>103</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mo>#</mml:mo><mml:mn>114</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mo>#</mml:mo><mml:mn>125</mml:mn><mml:mo>,</mml:mo><mml:mo>#</mml:mo><mml:mn>121</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and <inline-formula id="IE66"><mml:math id="IM66" display="inline" overflow="scroll"><mml:mrow><mml:mo>#</mml:mo><mml:mn>118</mml:mn></mml:mrow></mml:math></inline-formula> were relatively large substructures (Molecular Weight: 221 through 876) from the DrugBank dataset (these structures are shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S6</xref>). Many of the important substructures had alkyl chains and aromatic rings, while the number of hydrogen bond donors and acceptors were small, indicating that there were many hydrophobic structures. In fact, the standardized logP(o/w) of these substructures, indicating extreme hydrophobicity compared with other substructures (e.g. alanine was –0.48), such as 2.54 for <inline-formula id="IE67"><mml:math id="IM67" display="inline" overflow="scroll"><mml:mrow><mml:mo>#</mml:mo><mml:mn>118</mml:mn></mml:mrow></mml:math></inline-formula> and 1.26 for <inline-formula id="IE68"><mml:math id="IM68" display="inline" overflow="scroll"><mml:mrow><mml:mo>#</mml:mo><mml:mn>125</mml:mn></mml:mrow></mml:math></inline-formula>. In contrast, hydrophilic substructures had lower Saliency Scores (e.g. arginine ranked 78 out of all 126 substructures). These results suggest that the presence of the hydrophobic side chain is the primary factor that enhanced the PPB rate. Indeed, HSA, which is most abundant in plasma proteins, has a hydrophobic binding pocket (<xref rid="btab726-B19" ref-type="bibr">Lambrinidis <italic toggle="yes">et al.</italic>, 2015</xref>). A high binding rate with HSA may be obtained in the presence of a structure that can bind to the hydrophobic binding pocket, such as fatty acids (<xref rid="btab726-B24" ref-type="bibr">Schmidt <italic toggle="yes">et al.</italic>, 2013</xref>), which is in accordance with our results.</p>
    </sec>
  </sec>
  <sec>
    <title>4 Discussion</title>
    <sec>
      <title>4.1 Selected descriptors</title>
      <p>In descriptor selection, the hyperparameter <italic toggle="yes">α</italic> of Lasso was changed by 0.2 steps in the range of 0.5 through 4.9. <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S6</xref> shows the top seven frequently selected descriptors with varying <italic toggle="yes">α</italic>. Descriptors for lipophilicity (logP(o/w), SlogP etc.), hydrophilicity (logS) and partial charge (PEOE_VSA-1, PEOE_VSA_FPNEG) were often selected regardless of the value of <italic toggle="yes">α</italic>. Lipophilicity-related descriptors are important for PPB rate prediction (<xref rid="btab726-B15" ref-type="bibr">Ingle <italic toggle="yes">et al.</italic>, 2016</xref>; <xref rid="btab726-B19" ref-type="bibr">Lambrinidis <italic toggle="yes">et al.</italic>, 2015</xref>). Among them, logP(o/w), the logarithm of the water-octanol partition coefficient, is moderately correlated with the PPB rate (<italic toggle="yes">R</italic> with <inline-formula id="IE69"><mml:math id="IM69" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi>P</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn><mml:mo>−</mml:mo><mml:mn>95</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> is 0.68). Hydrophobic compounds with a negative charge tend to bind to HSA well. Therefore, partial charge-related descriptors that depend on the ionization state of the peptide, in addition to lipophilicity descriptors, may enhance prediction performance. The relationship between ionization states and prediction accuracy is discussed further in <xref rid="sup1" ref-type="supplementary-material">Supplementary Text S3</xref>. Most 3D descriptors calculated by MOE were related to potential energy, polar surface area, etc., and no 3D descriptors appeared among the top seven in any hyperparameter <italic toggle="yes">α</italic>. Cyclic peptides in the PD dataset and Tajimi dataset might be described only with 2D descriptors that do not use any 3D structural information.</p>
      <p>With respect to learning time and overfitting, it is desirable to use minimal number of descriptors. Accordingly, three descriptors (logP(o/w), PEOE_VSA-1, logS) consistently selected with the range of <inline-formula id="IE70"><mml:math id="IM70" display="inline" overflow="scroll"><mml:mrow><mml:mo>α</mml:mo><mml:mo>=</mml:mo><mml:mn>4.3</mml:mn></mml:mrow></mml:math></inline-formula> through 4.9 were used. The extraction of descriptors facilitated the training of prediction models, although the training data were less extensive than that of general deep learning models. The distribution of the selected whole-peptide descriptors and that of the objective variable are shown in <xref rid="btab726-F5" ref-type="fig">Figure  5</xref>, while the distribution of substructure descriptors is shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S7</xref>. All three whole-peptide descriptors had a correlation with the objective variable (<inline-formula id="IE71"><mml:math id="IM71" display="inline" overflow="scroll"><mml:mrow><mml:mo>|</mml:mo><mml:mi>R</mml:mi><mml:mo>|</mml:mo><mml:mo>=</mml:mo><mml:mn>0.61</mml:mn></mml:mrow></mml:math></inline-formula> through 0.68). Peptides of the external test data were widely distributed with reference to logP(o/w) but were biased with reference to the other two descriptors. Therefore, it is considered difficult to predict the PPB rate of the external test data with a single descriptor alone.</p>
      <fig position="float" id="btab726-F5">
        <label>Fig. 5.</label>
        <caption>
          <p>Distribution of three selected whole-peptide descriptors and objective variables. Cyclic peptides in training data, internal test data and external test data (DrugBank dataset) are shown as blue, red and green dots, respectively</p>
        </caption>
        <graphic xlink:href="btab726f5" position="float"/>
      </fig>
    </sec>
    <sec>
      <title>4.2 Principal component analysis revealed the effectiveness of the descriptor selection</title>
      <p>To compare the property distributions of internal and external test data relative to the training data, principal component analysis (PCA) was performed. The internal and external test data were converted using the eigenvectors obtained from the training data. From the results shown in <xref rid="btab726-F6" ref-type="fig">Figure  6A</xref>, various cyclic peptides spreading in the principal component space were selected as the test data by the KS algorithm. However, the summed contribution rate of both PC1 and PC2 was approximately 40%, and it was difficult to distinguish whether the PPB rate was over 80% or not, based on these two components. Some cyclic peptides from the external test data seemed dissimilar to all peptides of the training data. In contrast, the PCA space with three selected descriptors (<xref rid="btab726-F6" ref-type="fig">Fig.  6B</xref>) showed that the external test data were almost in the same range as the training data, despite the unique structures of the cyclic peptides in the external test data. The results indicated that the PPB rate of the external test data can be predicted using selected descriptors. Though it is difficult to distinguish between the high <inline-formula id="IE72"><mml:math id="IM72" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula> and low <inline-formula id="IE73"><mml:math id="IM73" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula> of external test data with PC1 only, it is possible to distinguish internal test data to some extent. If the PC1 value was less than 0.0, the PPB rate tended to be 80% or higher for training and internal test data. When the value of PC1 exceeded 2.0, the PPB rate tended to be less than 80% for training and internal test data. Thus, the appropriate whole-peptide descriptors were successfully selected by the proposed descriptor selection procedure.</p>
      <fig position="float" id="btab726-F6">
        <label>Fig. 6.</label>
        <caption>
          <p>Distribution of each dataset in PCA space, with the first principal component (PC1) as the horizontal axis and the second principal component (PC2) as the vertical axis. The contribution rates are shown in the parentheses of axes captions: (<bold>A</bold>) before descriptor selection (147 descriptors), (<bold>B</bold>) after descriptor selection (three descriptors). High and low indicate data with %<inline-formula id="IE74"><mml:math id="IM74" display="inline" overflow="scroll"><mml:mrow><mml:mi mathvariant="italic">PPB</mml:mi><mml:mo>≥</mml:mo><mml:mn>80</mml:mn></mml:mrow></mml:math></inline-formula>% and %<italic toggle="yes">PPB</italic> &lt; 80%, respectively. Blue and light blue indicate training data, red and orange indicate internal test data and green and yellow-green indicate external test (DrugBank) data</p>
        </caption>
        <graphic xlink:href="btab726f6" position="float"/>
      </fig>
    </sec>
    <sec>
      <title>4.3 Analysis of acetyl-daptomycin and daptomycin predictions with similar main structures</title>
      <p>The external test (DrugBank) data contained some structurally similar pairs. We analyzed the prediction results of acetyl-daptomycin and daptomycin (<xref rid="btab726-F7" ref-type="fig">Fig.  7</xref>) among them, which differed only in the fatty acid side chain corresponding to the substructures <inline-formula id="IE75"><mml:math id="IM75" display="inline" overflow="scroll"><mml:mrow><mml:mo>#</mml:mo><mml:mn>124</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula id="IE76"><mml:math id="IM76" display="inline" overflow="scroll"><mml:mrow><mml:mo>#</mml:mo><mml:mn>125</mml:mn></mml:mrow></mml:math></inline-formula>. According to the results of <xref rid="btab726-B25" ref-type="bibr">Schneider <italic toggle="yes">et al.</italic> (2017)</xref>, the N-terminal fatty acid side chain of daptomycin (substructure <inline-formula id="IE77"><mml:math id="IM77" display="inline" overflow="scroll"><mml:mrow><mml:mo>#</mml:mo><mml:mn>125</mml:mn></mml:mrow></mml:math></inline-formula>) specifically binds to HSA by deeply piercing the binding pocket Site 1, resulting in the high PPB rate (92%). In contrast, acetyl-daptomycin does not have the fatty acid side chain, resulting in the low PPB rate (12%). These differences, however, were hardly reflected to whole-peptide descriptors; thus, <xref rid="btab726-B28" ref-type="bibr">Tajimi <italic toggle="yes">et al.</italic> (2018)</xref> reported that it was difficult to distinguish them (predicted <inline-formula id="IE78"><mml:math id="IM78" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi></mml:mrow></mml:math></inline-formula> value by Tajimi of acetyl-daptomycin: 18%; daptomycin: 49%). The same tendency was obtained with our whole-peptide descriptor-based models (comparison models 2 and 3, predicted <inline-formula id="IE79"><mml:math id="IM79" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi>P</mml:mi><mml:mi>P</mml:mi><mml:msub><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn><mml:mo>−</mml:mo><mml:mn>95</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> value of acetyl-daptomycin: 51% through 56%; daptomycin: 53% through 57%).</p>
      <fig position="float" id="btab726-F7">
        <label>Fig. 7.</label>
        <caption>
          <p>The structures, the substructures obtained by the decomposition procedure, their substructure numbers, and the heatmap of Salience Score of acetyl-daptomycin (Exp.<inline-formula id="IE80"><mml:math id="IM80" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi><mml:mo>=</mml:mo></mml:mrow></mml:math></inline-formula> 12%, Pred.<inline-formula id="IE81"><mml:math id="IM81" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi><mml:mo>=</mml:mo></mml:mrow></mml:math></inline-formula> 53%) and daptomycin (Exp.<inline-formula id="IE82"><mml:math id="IM82" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi><mml:mo>=</mml:mo></mml:mrow></mml:math></inline-formula> 92%, Pred.<inline-formula id="IE83"><mml:math id="IM83" display="inline" overflow="scroll"><mml:mrow><mml:mo>%</mml:mo><mml:mi mathvariant="italic">PPB</mml:mi><mml:mo>≥</mml:mo></mml:mrow></mml:math></inline-formula> 95%). The heatmap of the Salience Score shows the average value of the Salience Score of all augmentation replicas, and the horizontal axis shows the substructure number</p>
        </caption>
        <graphic xlink:href="btab726f7" position="float"/>
      </fig>
      <p>However, our CycPeptPPB model, which is based on substructure descriptors, correctly predicted their PPB rates. From the heat map of Salience Score shown in <xref rid="btab726-F7" ref-type="fig">Figure  7</xref>, both <inline-formula id="IE84"><mml:math id="IM84" display="inline" overflow="scroll"><mml:mrow><mml:mo>#</mml:mo><mml:mn>124</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula id="IE85"><mml:math id="IM85" display="inline" overflow="scroll"><mml:mrow><mml:mo>#</mml:mo><mml:mn>125</mml:mn></mml:mrow></mml:math></inline-formula> attracted the most attention from the prediction model, and the model distinguished the structural change even though these two structures were not utilized in model training. The prediction values and analysis suggested that the proposed method with substructure descriptors was effective. It also revealed that the Saliency Score could detect important side chains.</p>
    </sec>
  </sec>
  <sec>
    <title>5 Conclusion</title>
    <p>In this study, a high-performance PPB rate prediction model, CycPeptPPB, for cyclic peptides based on deep learning techniques was proposed. CycPeptPPB model 2, utilizing data augmentation, succeeded in obtaining excellent prediction accuracy (<inline-formula id="IE86"><mml:math id="IM86" display="inline" overflow="scroll"><mml:mrow><mml:mtext>MAE</mml:mtext></mml:mrow></mml:math></inline-formula> of 4.79%, <inline-formula id="IE87"><mml:math id="IM87" display="inline" overflow="scroll"><mml:mi>R</mml:mi></mml:math></inline-formula> of 0.92) for external test data. This model was able to distinguish between the PPB of acetyl-daptomycin and daptomycin, which are similar in structure but differ with respect to PPB rate. Furthermore, we proposed the use of Salience Score as a method for identifying the substructures that are important for predicting PPB rate. The Salience Score can provide insight into actual drug development and support lead compound optimization. Although we provided 3D descriptors as well as 2D descriptors, no 3D descriptor was selected. Future improvements on the usage of 3D conformation information might contribute to better prediction performance. The proposed prediction method allows the selection and design of cyclic peptides with a high PPB rate, which reduces the failure rate in clinical tests and accelerates the development of cyclic peptide drugs.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btab726_supplementary_data</label>
      <media xlink:href="btab726_supplementary_data.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ack1">
    <title>Acknowledgement</title>
    <p>The authors thank PeptiDream Inc. for providing the PPB rate assay data regarding the cyclic peptides, and for insightful discussion.</p>
    <sec>
      <title>Funding</title>
      <p>This work was partially supported by the Program for Building Regional Innovation Ecosystems ‘Program to Industrialize an Innovative Middle Molecule Drug Discovery Flow through Fusion of Computational Drug Design and Chemical Synthesis Technology’ from the Ministry of Education, Culture, Sports, Science and Technology (MEXT); KAKENHI [17H01814, 20H04280] from the Japan Society for the Promotion of Science (JSPS); and the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) [JP20am0101112] from the Japan Agency for Medical Research and Development (AMED).</p>
      <p><italic toggle="yes">Conflict of Interest</italic>: none declared. </p>
    </sec>
  </ack>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btab726-B1">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Akiba</surname><given-names>T.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2019</year>) Optuna: a next-generation hyperparameter optimization framework. In: <italic toggle="yes">Proceedings of ACM KDD’19</italic>, Anchorage, AK, USA, pp. <fpage>2623</fpage>–<lpage>2631</lpage>.</mixed-citation>
    </ref>
    <ref id="btab726-B2">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Bach</surname><given-names>F.R.</given-names></string-name></person-group> (<year>2008</year>) Bolasso: model consistent lasso estimation through the bootstrap. In: <italic toggle="yes">Proceedings of ICML2008</italic>, Helsinki, Finland, pp. <fpage>33</fpage>–<lpage>40</lpage>.</mixed-citation>
    </ref>
    <ref id="btab726-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baehrens</surname><given-names>D.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2010</year>) <article-title>How to explain individual classification decisions</article-title>. <source>J. Mach. Learn. Res</source>., <volume>11</volume>, <fpage>1803</fpage>–<lpage>1831</lpage>.</mixed-citation>
    </ref>
    <ref id="btab726-B4">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Ban</surname><given-names>T.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2017</year>) Efficient hyperparameter optimization by using bayesian optimization for drug–target interaction prediction. In: <italic toggle="yes">Proceedings of ICCABS 2017</italic>, Orlando, FL, USA, pp. <fpage>1</fpage>–<lpage>6</lpage>.</mixed-citation>
    </ref>
    <ref id="btab726-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bhat</surname><given-names>A.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2015</year>) <article-title>Lead discovery and optimization strategies for peptide macrocycles</article-title>. <source>Eur. J. Med. Chem</source>., <volume>94</volume>, <fpage>471</fpage>–<lpage>479</lpage>.<pub-id pub-id-type="pmid">25109255</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cardote</surname><given-names>T.A.F.</given-names></string-name>, <string-name><surname>Ciulli</surname><given-names>A.</given-names></string-name></person-group> (<year>2016</year>) <article-title>Cyclic and macrocyclic peptides as chemical tools to recognise protein surfaces and probe protein–protein interactions</article-title>. <source>ChemMedChem</source>, <volume>11</volume>, <fpage>787</fpage>–<lpage>794</lpage>.<pub-id pub-id-type="pmid">26563831</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cary</surname><given-names>D.R.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2017</year>) <article-title>Constrained peptides in drug discovery and development</article-title>. <source>J. Synth. Org. Chem. Jpn</source>., <volume>75</volume>, <fpage>1171</fpage>–<lpage>1178</lpage>.</mixed-citation>
    </ref>
    <ref id="btab726-B8">
      <mixed-citation publication-type="book">Chemical Computing Group Inc. (<year>2019</year>) <source>Molecular Operating Environment (MOE), 2019.01</source>. <publisher-loc>Montreal, QC, Canada</publisher-loc>.</mixed-citation>
    </ref>
    <ref id="btab726-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>L.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>X.</given-names></string-name></person-group> (<year>2012</year>) <article-title>Results of molecular docking as descriptors to predict human serum albumin binding affinity</article-title>. <source>J. Mol. Graph. Model</source>., <volume>33</volume>, <fpage>35</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">22153983</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B10">
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Eitel</surname><given-names>A.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2015</year>) Multimodal deep learning for robust rgb-d object recognition. In: <italic toggle="yes">Proceedings of IEEE IROS2015</italic>, Hamburg, Germany, pp. <fpage>681</fpage>–<lpage>687</lpage>.</mixed-citation>
    </ref>
    <ref id="btab726-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Galvao</surname><given-names>R.K.H.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2005</year>) <article-title>A method for calibration and validation subset partitioning</article-title>. <source>Talanta</source>, <volume>67</volume>, <fpage>736</fpage>–<lpage>740</lpage>.<pub-id pub-id-type="pmid">18970233</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Garcia-Diaz</surname><given-names>A.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2012</year>) <article-title>Saliency from hierarchical adaptation through decorrelation and variance normalization</article-title>. <source>Image Vis. Comput</source>., <volume>30</volume>, <fpage>51</fpage>–<lpage>64</lpage>.</mixed-citation>
    </ref>
    <ref id="btab726-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gumede</surname><given-names>N.J.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2012</year>) <article-title>Experimental-like affinity constants and enantioselectivity estimates from flexible docking</article-title>. <source>J. Chem. Inf. Model</source>., <volume>52</volume>, <fpage>2754</fpage>–<lpage>2759</lpage>.<pub-id pub-id-type="pmid">22946447</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hinton</surname><given-names>G.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2012</year>) <article-title>Deep neural networks for acoustic modeling in speech recognition: the shared views of four research groups</article-title>. <source>IEEE Signal Process. Mag</source>., <volume>29</volume>, <fpage>82</fpage>–<lpage>97</lpage>.</mixed-citation>
    </ref>
    <ref id="btab726-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ingle</surname><given-names>B.L.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2016</year>) <article-title>Informing the human plasma protein binding of environmental chemicals by machine learning in the pharmaceutical space: applicability domain and limits of predictability</article-title>. <source>J. Chem. Inf. Model</source>., <volume>56</volume>, <fpage>2243</fpage>–<lpage>2252</lpage>.<pub-id pub-id-type="pmid">27684444</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Isegawa</surname><given-names>M.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2013</year>) <article-title>Electrostatically embedded molecular tailoring approach and validation for peptides</article-title>. <source>J. Chem. Theory Comput</source>., <volume>9</volume>, <fpage>1381</fpage>–<lpage>1393</lpage>.<pub-id pub-id-type="pmid">26587600</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Katrina</surname><given-names>W.L.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2014</year>) <article-title>A structure-based model for predicting serum albumin binding</article-title>. <source>PLoS One</source>, <volume>9</volume>, <fpage>e93323</fpage>.<pub-id pub-id-type="pmid">24691448</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B18">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Kümmerer</surname><given-names>M.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2014</year>) <part-title>Deep Gaze I: boosting saliency prediction with feature maps trained on ImageNet</part-title>. In: <source>Proceedings of ICLR2015</source>, <publisher-loc>San Diego, CA, USA</publisher-loc>, pp. <fpage>1</fpage>–<lpage>12</lpage>.</mixed-citation>
    </ref>
    <ref id="btab726-B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lambrinidis</surname><given-names>G.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2015</year>) <article-title>In vitro, in silico and integrated strategies for the estimation of plasma protein binding. a review</article-title>. <source>Adv. Drug Deliv. Rev</source>., <volume>86</volume>, <fpage>27</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">25819487</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>H.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2011</year>) <article-title>Predicting human plasma protein binding of drugs using plasma protein interaction QSAR analysis (PPI-QSAR)</article-title>. <source>Biopharm. Drug Dispos</source>., <volume>32</volume>, <fpage>333</fpage>–<lpage>342</lpage>.<pub-id pub-id-type="pmid">21800312</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Prentis</surname><given-names>R.</given-names></string-name></person-group>  <etal>et al</etal> (<year>1988</year>) <article-title>Pharmaceutical innovation by the seven uk-owned pharmaceutical companies (1964–1985)</article-title>. <source>Br. J. Clin. Pharmacol</source>., <volume>25</volume>, <fpage>387</fpage>–<lpage>396</lpage>.<pub-id pub-id-type="pmid">3358900</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sato</surname><given-names>R.</given-names></string-name>, <string-name><surname>Ishida</surname><given-names>T.</given-names></string-name></person-group> (<year>2019</year>) <article-title>Protein model accuracy estimation based on local structure quality assessment using 3D convolutional neural network</article-title>. <source>PLoS One</source>, <volume>14</volume>, <fpage>e0221347</fpage>.<pub-id pub-id-type="pmid">31487288</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scheife</surname><given-names>R.T.</given-names></string-name></person-group> (<year>1989</year>) <article-title>Protein binding: what does it mean?</article-title>  <source>Drug Intell. Clin. Pharm</source>., <volume>23</volume>, <fpage>S27</fpage>–<lpage>S31</lpage>.</mixed-citation>
    </ref>
    <ref id="btab726-B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schmidt</surname><given-names>M.M.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2013</year>) <article-title>Crystal structure of an hsa/fcrn complex reveals recycling by competitive mimicry of hsa ligands at a ph-dependent hydrophobic interface</article-title>. <source>Structure</source>, <volume>21</volume>, <fpage>1966</fpage>–<lpage>1978</lpage>.<pub-id pub-id-type="pmid">24120761</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schneider</surname><given-names>E.K.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2017</year>) <article-title>Plasma protein binding structure–activity relationships related to the n-terminus of daptomycin</article-title>. <source>ACS Infect. Dis</source>., <volume>3</volume>, <fpage>249</fpage>–<lpage>258</lpage>.<pub-id pub-id-type="pmid">28142234</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B26">
      <mixed-citation publication-type="book">Simulations Plus Inc. (<year>2020</year>) <source>ADMET Predictor 10.0</source>. <publisher-loc>Lancaster, CA, USA</publisher-loc>.</mixed-citation>
    </ref>
    <ref id="btab726-B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sun</surname><given-names>L.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2018</year>) <article-title>In silico prediction of compounds binding to human plasma proteins by qsar models</article-title>. <source>ChemMedChem</source>, <volume>13</volume>, <fpage>572</fpage>–<lpage>581</lpage>.<pub-id pub-id-type="pmid">29057587</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tajimi</surname><given-names>T.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2018</year>) <article-title>Computational prediction of plasma protein binding of cyclic peptides from small molecule experimental data using sparse modeling techniques</article-title>. <source>BMC Bioinform</source>., <volume>19</volume>, <fpage>527</fpage>.</mixed-citation>
    </ref>
    <ref id="btab726-B29">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tibshirani</surname><given-names>R.</given-names></string-name></person-group> (<year>1996</year>) <article-title>Regression shrinkage and selection via the lasso</article-title>. <source>J. R. Stat. Soc. Ser. B Stat. Methodol</source>., <volume>58</volume>, <fpage>267</fpage>–<lpage>288</lpage>.</mixed-citation>
    </ref>
    <ref id="btab726-B30">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Tokui</surname><given-names>S.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2015</year>) <part-title>Chainer: a next-generation open source framework for deep learning</part-title>. In: <source>Proceedings of LearningSys in NIPS2015</source>, <volume>Vol. 5</volume>, <publisher-name>Montreal, QC, Canada</publisher-name>, pp. <fpage>1</fpage>–<lpage>6</lpage>.</mixed-citation>
    </ref>
    <ref id="btab726-B31">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Verdine</surname><given-names>G.L.</given-names></string-name>, <string-name><surname>Walensky</surname><given-names>L.D.</given-names></string-name></person-group> (<year>2007</year>) <article-title>The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members</article-title>. <source>Clin. Cancer Res</source>., <volume>13</volume>, <fpage>7264</fpage>–<lpage>7270</lpage>.<pub-id pub-id-type="pmid">18094406</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B32">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vinogradov</surname><given-names>A.A.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2019</year>) <article-title>Macrocyclic peptides as drug candidates: recent progress and remaining challenges</article-title>. <source>J. Am. Chem. Soc</source>., <volume>141</volume>, <fpage>4167</fpage>–<lpage>4181</lpage>.<pub-id pub-id-type="pmid">30768253</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B33">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Watanabe</surname><given-names>R.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2018</year>) <article-title>Predicting fraction unbound in human plasma from chemical structure: improved accuracy in the low value ranges</article-title>. <source>Mol. Pharm</source>., <volume>15</volume>, <fpage>5302</fpage>–<lpage>5311</lpage>.<pub-id pub-id-type="pmid">30259749</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B34">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>D.S.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2018</year>) <article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res</source>., <volume>46</volume>, <fpage>D1074</fpage>–<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B35">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname><given-names>X.W.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2013</year>) <article-title>The use of pseudo-equilibrium constant affords improved qsar models of human plasma protein binding</article-title>. <source>Pharm. Res</source>., <volume>30</volume>, <fpage>1790</fpage>–<lpage>1798</lpage>.<pub-id pub-id-type="pmid">23568522</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B36">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zorzi</surname><given-names>A.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2017</year>) <article-title>Cyclic peptide therapeutics: past, present and future</article-title>. <source>Curr. Opin. Chem. Biol</source>., <volume>38</volume>, <fpage>24</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="pmid">28249193</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B37">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zsila</surname><given-names>F.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2011</year>) <article-title>Evaluation of drug–human serum albumin binding interactions with support vector machine aided online automated docking</article-title>. <source>Bioinformatics</source>, <volume>27</volume>, <fpage>1806</fpage>–<lpage>1813</lpage>.<pub-id pub-id-type="pmid">21593135</pub-id></mixed-citation>
    </ref>
    <ref id="btab726-B38">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zuo</surname><given-names>Z.-L.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2014</year>) <article-title>Free energy of binding of coiled-coil complexes with different electrostatic environments: the influence of force field polarisation and capping</article-title>. <source>Nat. Prod. Bioprospect</source>., <volume>4</volume>, <fpage>285</fpage>–<lpage>295</lpage>.<pub-id pub-id-type="pmid">25159896</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
